Dupilumab-Associated Blepharoconjunctivitis: Clinical and Morphological Aspects

被引:1
|
作者
Serino, Federica [1 ,2 ]
Dattilo, Valeria [1 ,2 ]
Cennamo, Michela [1 ,2 ]
Roszkowska, Anna Maria [3 ]
Gola, Massimo [4 ]
Magliulo, Manfredi [4 ]
Magnaterra, Elisabetta [4 ]
Mencucci, Rita [1 ,2 ]
机构
[1] Careggi Univ Hosp, Neuromuscular & Sense Organs Dept, Eye Clin, I-50139 Florence, Italy
[2] Univ Florence, Dept Neurosci Psychol Drug Res & Child Hlth, I-50019 Florence, Italy
[3] Univ Messina, Dept Biomed & Dent Sci & Morphofunct Imaging, I-98166 Messina, Italy
[4] Azienda USL Toscana Ctr, Allergol & Pediat Dermatol Unit, I-50122 Florence, Italy
关键词
Dupilumab; atopic dermatitis; meibomian glands; cornea; DRY EYE DISEASE; ATOPIC-DERMATITIS;
D O I
10.3390/biomedicines11123104
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Purpose: To describe the clinical and morphologic changes in the ocular surface microstructure of patients affected with moderate-to-severe Atopic Dermatitis (AD) before and during Dupilumab treatment. Methods: This is a monocentric observational study on thirty-three patients affected with AD before and during Dupilumab treatment. All patients underwent a slit-lamp examination: complete clinical assessment, Break Up Time test (BUT), Schirmer test, and corneal staining grading (Oxford scale) were performed. Meibomian Glands Dysfunction (MGD) evaluation (Meibography), Non-invasive Keratograph Break Up Time test (NIKBUT), Tear Meniscus Height (TMH), and ocular Redness Score (RS) have been investigated using an OCULUS Keratograph. In vivo images of the conjunctiva, cornea, and meibomian glands have been acquired by confocal microscopy. Results: Sixty-six eyes were included in our study: twenty-two eyes of 11 naive patients with indication for treatment but not in therapy yet (Group 1) and forty-four eyes of 22 patients treated with Dupilumab for at least 4 months (subcutaneous administration of 300 mg every 2 weeks) (Group 2). Either patients treated with Dupilumab or naive patients with moderate-to-severe forms of AD had a tear film instability (TBUT and NIKBUT reduced), whereas the quantity of the tear film was overall normal (Schirmer test and TMH), without statistically significant differences between the two groups. When Meibography was performed with the Keratograph, the difference between Group 1 and Group 2 was statistically significant in terms of Meiboscore (p = 0.0043 and p = 0.0242, respectively), as well as the difference in terms of mean RS. These results paired well with the confocal microscopy results in which we found a decrease in the goblet cell population in the conjunctival epithelium in the treated group (5.2 cells/mm), along with inflammatory cells that were more concentrated around the adenoid lumina of the meibomian glands. Conclusions: In recent years, the use of Dupilumab has been increasing, but mild-to-severe conjunctivitis is a common side effect. Our major results demonstrate a loss of meibomian glands at the Keratograph examination: we can assume a reduced meibum secretion and an evaporative dry eye with MGD. We suggest that the inflammation of the ocular surface may involve not only the cornea and the conjunctiva, but also the meibomian glands, and Dupilumab may play a role. However, the frequency of clear conjunctivitis is not as common as reported in the literature.
引用
收藏
页数:10
相关论文
共 50 条
  • [11] Dupilumab-associated hypereosinophilia in severe asthma
    Strong, April
    Lin, Tiffany
    Sverrild, Asger
    Mackay, Anna
    Lee, Joy
    Zubrinich, Celia
    Pham, Jonathan
    Bosco, Julian
    Denton, Eve
    Dols, Monique
    Stirling, Robert G.
    Dabscheck, Eli
    Iyer, Jhanavi
    Gillman, Andrew
    Hew, Mark
    ERJ OPEN RESEARCH, 2024, 10 (04)
  • [12] Dupilumab-Associated Mucin Deficiency (DAMD)
    Barnett, Brad P.
    Afshari, Natalie A.
    TRANSLATIONAL VISION SCIENCE & TECHNOLOGY, 2020, 9 (03):
  • [14] Pathomechanism of dupilumab-associated inflammatory eye symptoms
    Wohlrab, J.
    Werfel, T.
    Wollenberg, A.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 (11) : E435 - E436
  • [15] Learning About Dupilumab-Associated Conjunctivitis Reply
    Treister, Alison D.
    Kraff-Cooper, Cheryl
    Lio, Peter A.
    JAMA DERMATOLOGY, 2019, 155 (06) : 754 - 755
  • [16] Management of dupilumab-associated conjunctivitis in atopic dermatitis
    Aszodi, Nora
    Thurau, Stephan
    Seegraeber, Marlene
    de Bruin-Weller, Marjolein
    Wollenberg, Andreas
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2019, 17 (05): : 488 - 492
  • [17] Dupilumab-associated facial dermatitis: A case series
    Milgraum, David
    Jamgochian, Marielle
    Wassef, Cindy
    Pappert, Amy
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB76 - AB76
  • [18] Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis
    Liberman, Paulina
    Shifera, Amde Selassie
    Berkenstock, Meghan
    CORNEA, 2020, 39 (06) : 784 - 786
  • [19] Dupilumab-associated inflammatory arthritis: a literature review
    Napolitano, Maddalena
    Ruggiero, Angelo
    Patruno, Cataldo
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2024, 49 (04) : 307 - 312
  • [20] Dupilumab-Associated Bilateral Conjunctival Papillomas and Corneal Perforation
    Dewhurst, Nicholas
    Larney, Conor
    Jobson, Dale
    Nofal, Nour
    Chong, Alvin
    Chan, Elsie
    CORNEA, 2025, 44 (02) : 250 - 254